ALCON INC (ALC) Stock News
NYSE:ALC - New York Stock Exchange, Inc. - CH0432492467 - Common Stock - Currency: USD
ALC Latest News, Press Relases and Analysis
Ahead of Alcon (ALC) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Alcon (ALC) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Alcon Announces Results of 2025 Annual General Meeting
Do Options Traders Know Something About Alcon Stock We Don't?
Investors need to pay close attention to ALC stock based on the movements in the options market lately.
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC)
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The majority of growth indexes entered correction territory during the quarter, due to pressure from the chaotic tariff implementation, concerns about a weakening U.S. economy, and increased inflation. […]
Mentions: TSLA
Alcon Publishes Agenda for 2025 Annual General Meeting
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities
Alcon Eyes Surgical Edge With LENSAR Buyout: Details
Alcon is set to acquire LENSAR Inc. in a $356 million deal. This acquisition includes LENSAR's advanced cataract laser technologies, boosting Alcon's offerings in femtosecond laser-assisted cataract surgery.
Mentions: LNSR
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024
ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Alcon to Host 2025 Capital Markets Day
Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension
Alcon to Present at 2025 Annual J.P. Morgan Healthcare Conference
Alcon Reports Solid Third-Quarter 2024 Results, including Double-Digit Earnings Growth and Record Cash Generation
Alcon Debuts Groundbreaking PRECISION7, a One-Week Replacement Contact Lens to Start and End Every Week Fresh
Alcon Innovations on Display at AAO 2024 Demonstrate Efficiency and Performance
ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alcon (NYSE:ALC) just reported results for the second quarter of 2024.Alcon rep...
